Pancreatic Cancer Risk During IPMN Surveillance: What a SEER-Based Study Found
Intraductal papillary mucinous neoplasms, or IPMNs, are cystic lesions of the pancreas that can sometimes turn into cancer. Because of that possibility, patients are often followed closely with long-term imaging. A new study published in Annals of Surgery compared the risk of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, in people under IPMN surveillance with a large population-based cohort from the Surveillance, Epidemiology, and End Results program, known as SEER.
The key question was simple but important: how much of the cancer risk seen during IPMN surveillance is truly above the background risk in the general population? The answer helps doctors decide who needs the most intensive follow-up and who may be able to avoid unnecessary scans.
Why IPMN Surveillance Matters
IPMNs are not the same as ordinary pancreatic cysts. They are considered pre-malignant, meaning some can eventually develop into invasive pancreatic cancer or a high-grade precancerous change. For that reason, many patients are advised to undergo lifelong surveillance, usually with MRI or CT imaging at regular intervals.
However, surveillance is not perfect. Some patients progress to cancer despite yearly imaging, while others never show meaningful cyst change over many years. This creates a difficult balance between early detection and the burden of repeated scans, anxiety, and healthcare cost. The true cancer risk attributable to IPMN has remained uncertain, especially when compared with people of the same age in the general population.
How the Study Was Conducted
Researchers performed a retrospective review of 1,494 patients who were being monitored for IPMN at a high-volume pancreatic center. The patients came from an institutional cyst database that included demographic information, serial imaging findings, and pathology results when available.
During follow-up, the cohort underwent 11,107 imaging scans. The median surveillance time was 55.3 months, and the total observation period reached 7,681 person-years at risk. The median age at the time of surveillance was 66 years, 64% of the patients were women, and the median initial cyst size was 1.4 cm.
To measure how much higher the cancer risk was than expected, the investigators calculated a standardized incidence ratio, or SIR. This compares the number of cancers actually observed in the study group with the number expected based on age- and year-matched SEER data.
Main Findings
Over the surveillance period, the cumulative incidence of malignancy at 60 months was 0.97%, with a confidence interval of 0.53% to 1.70%. In other words, fewer than 1 in 100 patients developed malignancy by five years, but the risk was not uniform across the population.
Compared with the SEER-matched population, the overall risk of pancreatic ductal adenocarcinoma during IPMN surveillance was about 10 times higher than expected. There were 26 cancer events in total, including 16 cases of IPMN with high-grade dysplasia and 10 cases of invasive pancreatic ductal adenocarcinoma, compared with 2.44 cases expected in the matched general population.
This finding confirms that people under IPMN surveillance do have a clearly elevated cancer risk, even when many lesions remain stable on imaging.
Who Was at Highest Risk?
The study also showed that not all patients carry the same level of risk. Certain clinical and imaging features were associated with much higher cancer rates.
The highest risk was seen in patients with main pancreatic duct, or MPD, dilation of 5 mm or more. Their SIR was 26.5, meaning their observed cancer rate was more than 26 times the expected population rate. Patients with a body mass index, or BMI, of 30 or higher also had a markedly increased risk, with an SIR of 20.6.
By contrast, some groups came closer to the risk seen in the general population. Patients with cysts 1 cm or smaller had a lower SIR of 3.28, and patients younger than 60 years had an SIR of 6.27. Even though these numbers were still above background population risk, they were substantially lower than the high-risk groups.
Importantly, even cysts that were considered guideline-negative, meaning they were smaller than 3 cm and lacked MPD dilation or a solid component, still had an elevated SIR of 8.40. This suggests that current guideline criteria identify risk fairly well, but they do not eliminate it completely.
What the Results Mean in Practice
The findings support a more personalized surveillance strategy for pancreatic cysts. In current practice, many patients with IPMN receive similar follow-up schedules even though their actual risk may be very different. This study suggests that patient factors such as age and obesity, as well as cyst features such as duct dilation and the presence of a solid component, should influence how closely a patient is followed.
For higher-risk patients, more intensive surveillance may improve the chance of detecting cancer at an earlier, more treatable stage. For lower-risk patients, less frequent imaging may reduce unnecessary procedures without greatly increasing the chance of missing clinically important disease.
At the same time, the study does not suggest stopping surveillance altogether for low-risk patients. Even in the lowest-risk groups, the cancer risk remained above that of the general population. Instead, the data support tailoring follow-up intervals and imaging choices based on individual risk.
Clinical Context and Limitations
As with any retrospective study, there are limitations. The data came from a single high-volume center, which may mean the results are not identical in all practice settings. Patients treated at specialized centers may also differ from the general community in important ways, including referral patterns and the intensity of follow-up.
In addition, standardized incidence ratios compare the study group with a population registry, but they do not prove that IPMN directly causes every observed cancer. Some patients may have had an underlying predisposition to pancreatic cancer unrelated to the cyst itself. Even so, the elevated risk is clinically meaningful because it affects surveillance decisions.
The study also reinforces a known challenge in pancreatic cyst care: imaging features are helpful, but they are not perfect predictors. Biomarkers, molecular testing of cyst fluid, improved imaging techniques, and risk models may all play a future role in refining surveillance strategies.
Take-Home Message
This SEER-based comparison shows that patients under surveillance for IPMN face a significantly higher risk of pancreatic cancer than the general population, but the risk is not the same for everyone. Main pancreatic duct dilation and obesity were associated with especially high risk, while younger patients and those with very small cysts had risk closer to baseline.
The practical message is that IPMN surveillance should not be one-size-fits-all. A personalized approach may help detect cancer earlier in high-risk patients while reducing the burden of repeated imaging in lower-risk groups. For patients, this study underscores the importance of regular follow-up and ongoing discussion with a pancreas specialist about individualized risk.
Reference: Choubey AP, Chou JF, Alessandris R, et al. Pancreas Cancer Risk During Intraductal Papillary Mucinous Neoplasm Surveillance – A SEER-Based Comparison. Annals of Surgery. 2026.
